Dr. Reddy's Gets EIR from USFDA for Cuernavaca Plant in Mexico
Hyderabad-based Dr. Reddy’s Laboratories said it has received establishment inspection report (EIR) from the US health regulator for its Cuernavaca facility in Mexico. The company had earlier said in a regulatory filing that audit of its active pharmaceutical ingredient (API) Cuernavaca plant in Mexico by the United States Food and Drug Administration (USFDA) was completed with zero observations. As per the USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
RT Retatrutide 99% purity 5mg-60mg*10vials weight loss Peptide Top Quality local factory
$50-60/UNIT FOB
Effective Weight Loss Peptide Tirzepatide,Retatrutide, Cagrilintide, High Quality Ghk-Cu, Nad+ Lyophilized Powder
$120/UNIT FOB
2026-06-11
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
EPA Pressures Minnesota to Tackle Nitrate Threat in Drinking Water
-
FDA Proposes Nationwide Ban on Brominated Vegetable Oil (BVO) in Food Additives, Continues Safety Assessment of Chemicals
-
USDA-FSIS Initiates Year-Long Survey of Dioxins in Cattle, Swine, and Catfish Starting November
-
New Advance Notification Guidelines for Imported Foods Released by the United States
-
The world's first octreotide capsule was approved by the FDA!
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
Eli Lilly Acquires Verve Therapeutics for $1.3 Billion to Revolutionize Cardiovascular Treatments
-
India Hosts Policymakers from 22 Countries to Strengthen Global Drug Standards
-
India Hosts 22 Nations to Advance Global Drug Standards and Access to Medicines
-
Wojcicki Secures 23andMe with $305M Bid Regeneron Exits Auction
Recommend Reading
-
AbbVie’s $2.5B Drug Venetoclax Fails to Improve Survival in Phase 3 Trial
-
Eli Lilly to Launch Higher-Dose Weight-Loss Drug Zepbound at $499 Per Month
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
Novo Nordisk Sounds the Alarm: Growth Headwinds Loom Over Global Operations in 2026
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
This week, the price of polyester bottle chips fluctuated and rose
-
Cost Floor and Demand Constraints: Dichloromethane in Volatile Consolidation
-
This Week's Benzene Market Prices Rise in China (4.13-4.17)
-
This week, the caustic soda price was weak (4.13-4.17) in China
-
This Week's Styrene Market Slightly Declined (4.13-4.17) in China